Aspyrian, Goodwin team up in antibody-drug-conjugate venture

Aspyrian Therapeutics and Goodwin Biotechnology said on Tuesday that they will collaborate on the development and scaling processes of Aspyrian's new antibody drug conjugate (ADC) platform.

Aspyrian's platform is a near-infrared photo-immunotherapy technological platform that uses a laser of visible light to eliminate tumors and leave surrounding healthy tissue unharmed. This technology has been approved by the Food and Drug Administration (FDA) on an investigational basis. Other ADCs are limited by their toxic components at certain levels, which likely would not be an issue with this ADC.

"This is our company's first (investigational new drug [IND]) submission, and securing the IND was a crucial milestone for our company. It speaks about the quality, timeliness and process economics that Goodwin Biotechnology puts into every aspect of their work." Miguel Garcia-Guzman, president and chief scientific officer at Aspyrian Therapeutics, said.

The Goodwin team will facilitate the development and manufacture of the devices to meet the demands of  the testing process. The IND approval allows transport of the equipment across state lines as needed to fulfill clinical testing requirements.

"The team at Goodwin Biotechnology takes great pride in partnering with our clients and advancing their biopharmaceutical candidates through the development phase and to file INDs," SooYoung Lee, chief operating officer at Goodwin Biotechnology, said. "We have worked with numerous clients in the past, and it always reinforces our drive and commitment when we're able to add value to our clients and their product portfolio."